Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

The imperative to share clinical study reports: recommendations from the Tamiflu experience.

Doshi P, Jefferson T, Del Mar C.

PLoS Med. 2012;9(4):e1001201. doi: 10.1371/journal.pmed.1001201. Epub 2012 Apr 10. No abstract available.

2.

Open clinical trial data for all? A view from regulators.

Eichler HG, Abadie E, Breckenridge A, Leufkens H, Rasi G.

PLoS Med. 2012;9(4):e1001202. doi: 10.1371/journal.pmed.1001202. Epub 2012 Apr 10. No abstract available.

3.

The Tamiflu saga continues: will our conduct change after the publication of the latest systematic review on benefits and harms of oseltamivir?

Bachelet VC.

Medwave. 2014 May 20;14(4):e5953. doi: 10.5867/medwave.2014.04.5953. English, Spanish.

PMID:
25383799
4.

The Tamiflu trials.

Loder E, Tovey D, Godlee F.

BMJ. 2014 Apr 9;348:g2630. doi: 10.1136/bmj.g2630. No abstract available.

PMID:
24811414
5.

Why don't we have all the evidence on oseltamivir?

Godlee F, Clarke M.

BMJ. 2009 Dec 8;339:b5351. doi: 10.1136/bmj.b5351. No abstract available. Erratum in: BMJ. 2010;340:c405.

PMID:
19995815
6.

Questions remain over safety and effectiveness of oseltamivir.

Cohen D.

BMJ. 2012 Jan 17;344:e467. doi: 10.1136/bmj.e467. No abstract available.

PMID:
22252042
7.

[Neuraminidase inhibitors: effects still unclear].

Gillissen A.

Dtsch Med Wochenschr. 2012 Oct;137(41):2086. doi: 10.1055/s-0032-1329128. Epub 2012 Oct 2. German. No abstract available.

PMID:
23033163
8.

Roche offers researchers access to all Tamiflu trials.

Cohen D.

BMJ. 2013 Apr 4;346:f2157. doi: 10.1136/bmj.f2157. No abstract available.

PMID:
23558407
9.

What does oseltamivir do, and how will we know?

Groves T.

BMJ. 2013 Jul 24;347:f4687. doi: 10.1136/bmj.f4687. No abstract available.

PMID:
23884974
10.

[How safe was oseltamivir care in the flu pandemic?].

Holzgrabe U.

Pharm Unserer Zeit. 2011 Mar;40(2):151-4. Review. German. No abstract available.

PMID:
21630542
11.

Complications: tracking down the data on oseltamivir.

Cohen D.

BMJ. 2009 Dec 8;339:b5387. doi: 10.1136/bmj.b5387. No abstract available. Erratum in: BMJ. 2010;340:c406.

PMID:
19995818
12.

Tamiflu: what dermatologists need to know.

Bergstrom KG.

J Drugs Dermatol. 2010 Jan;9(1):76-8.

PMID:
20120431
13.

Is oseltamivir (Tamiflu) safe? Re-examining the Tamiflu 'ado' from Japan.

Okamoto E.

Expert Rev Pharmacoecon Outcomes Res. 2010 Feb;10(1):17-24. doi: 10.1586/erp.09.70. Review. Erratum in: Expert Rev Pharmacoecon Outcomes Res. 2010 Jun;10(3):345-6.

PMID:
20121561
14.

Roche continues to drag its feet on access to Tamiflu data.

G√łtzsche PC.

BMJ. 2013 May 15;346:f3001. doi: 10.1136/bmj.f3001. No abstract available.

PMID:
23678077
15.

Tug of war for antiviral drugs data.

Belluz J.

BMJ. 2014 Apr 9;348:g2227. doi: 10.1136/bmj.g2227. No abstract available.

PMID:
24811408
16.

Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review.

Toovey S, Rayner C, Prinssen E, Chu T, Donner B, Thakrar B, Dutkowski R, Hoffmann G, Breidenbach A, Lindemann L, Carey E, Boak L, Gieschke R, Sacks S, Solsky J, Small I, Reddy D.

Drug Saf. 2008;31(12):1097-114. doi: 10.2165/0002018-200831120-00006. Review.

PMID:
19026027
17.

Roche perspectives on Tamiflu.

Clinch B, Smith J.

Clin Microbiol Infect. 2015 Mar;21(3):226-9. doi: 10.1016/j.cmi.2015.01.014. Epub 2015 Jan 23. Review. No abstract available.

18.

Neuraminidase inhibitors--the story behind the Cochrane review.

Doshi P.

BMJ. 2009 Dec 8;339:b5164. doi: 10.1136/bmj.b5164. No abstract available.

PMID:
19995813
19.

Oseltamivir. EN 241104, GS 4104, RO 640796, Tamiflu.

[No authors listed]

Drugs R D. 1999 Sep;2(3):173-7. No abstract available.

PMID:
10641220
20.

Tamiflu still prudent for pandemic influenza, PHAC maintains.

Eggertson L.

CMAJ. 2010 Feb 9;182(2):E133-4. doi: 10.1503/cmaj.109-3145. Epub 2010 Jan 4. No abstract available.

Supplemental Content

Support Center